N-乙基羟胺盐酸盐 | 42548-78-7

• 物质功能分类: 医药中间体 - 原料药中间体
• 分子结构分类: 有机化合物 - 有机氮化合物
• 中文名称: N-乙基羟胺盐酸盐
• 英文名称: N-ethylhydroxylamine hydrochloride
• 英文别名: ethyl(hydroxy)azanium;chloride
• CAS: 42548-78-7
• 化学式: C₂H₈NO*Cl
• mdl: MFCD00144881
• 分子量: 97.5446
• InChiKey: LTZZYVWUGIPISL-UHFFFAOYSA-N

物化性质

• 熔点：
  37°C

计算性质

• 辛醇/水分配系数(LogP)：
  -0.16
• 重原子数：
  5
• 可旋转键数：
  1
• 环数：
  0.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  36.8
• 氢给体数：
  2
• 氢受体数：
  2

安全信息

• 海关编码：
  2928000090
• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H335
• 储存条件：
  室温和干燥环境下使用。

SDS

Name:	n-Ethylhydroxylamine hydrochloride 97% Material Safety Data Sheet
Synonym:
CAS:	42548-78-7

Section 1 - Chemical Product MSDS Name:n-Ethylhydroxylamine hydrochloride 97% Material Safety Data Sheet
Synonym:

---

Section 2 - COMPOSITION, INFORMATION ON INGREDIENTS

CAS#	Chemical Name	content	EINECS#
42548-78-7	N-ethylhydroxylamine hydrochloride,97%	HYDROCHL	unlisted

Hazard Symbols: Not available.
Risk Phrases:

---

Section 3 - HAZARDS IDENTIFICATION
EMERGENCY OVERVIEW
Hygroscopic.
Potential Health Effects
The toxicological properties of this material have not been investigated. Use appropriate procedures to prevent opportunities for direct contact with the skin or eyes and to prevent inhalation.

---

Section 4 - FIRST AID MEASURES
Eyes: Flush eyes with plenty of water for at least 15 minutes, occasionally lifting the upper and lower lids. Get medical aid immediately.
Skin:
Get medical aid. Flush skin with plenty of soap and water for at least 15 minutes while removing contaminated clothing and shoes.
Remove contaminated clothing and shoes.
Ingestion:
If victim is conscious and alert, give 2-4 cupfuls of milk or water.
Get medical aid immediately.
Inhalation:
Get medical aid immediately. Remove from exposure to fresh air immediately. If not breathing, give artificial respiration. If breathing is difficult, give oxygen.
Notes to Physician:
Treat symptomatically and supportively.

---

Section 5 - FIRE FIGHTING MEASURES
General Information:
As in any fire, wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear. During a fire, irritating and highly toxic gases may be generated by thermal decomposition or combustion.
Extinguishing Media:
Use agent most appropriate to extinguish fire.
Autoignition Temperature: Not available.
Flash Point: Not available.
NFPA Rating: Not published.
Explosion Limits, Lower: Not available.
Upper: Not available.

---

Section 6 - ACCIDENTAL RELEASE MEASURES
General Information: Use proper personal protective equipment as indicated in Section 8.
Spills/Leaks:
Clean up spills immediately, observing precautions in the Protective Equipment section.

---

Section 7 - HANDLING and STORAGE
Handling:
Wash thoroughly after handling. Remove contaminated clothing and wash before reuse. Avoid contact with eyes, skin, and clothing. Avoid ingestion and inhalation.
Storage:
Store in a cool, dry place. Keep container closed when not in use.

---

Section 8 - EXPOSURE CONTROLS, PERSONAL PROTECTION
Engineering Controls:
Use process enclosure, local exhaust ventilation, or other engineering controls to control airborne levels.
Personal Protective Equipment Eyes: Wear chemical goggles.
Skin:
Wear appropriate protective gloves to prevent skin exposure.
Clothing:
Wear appropriate protective clothing to minimize contact with skin.
Respirators:
A respiratory protection program that meets OSHA's 29 CFR 1910.134 and ANSI Z88.2 requirements must be followed whenever workplace conditions warrant a respirator's use.

---

Section 9 - PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Not available.
Appearance: clear yellow
Odor: Not available.
pH: Not available.
Vapor Pressure: Not available.
Vapor Density: Not available.
Evaporation Rate: Not available.
Viscosity: Not available.
Boiling Point: Not available.
Freezing/Melting Point: 37 deg C
Decomposition Temperature: Not available.
Solubility: Not available.
Specific Gravity/Density: Not available.
Molecular Formula: C2H7NO.HCl
Molecular Weight: 97.54

---

Section 10 - STABILITY AND REACTIVITY
Chemical Stability:
Stable under normal temperatures and pressures.
Conditions to Avoid:
Incompatible materials, strong oxidants.
Incompatibilities with Other Materials:
Not available.
Hazardous Decomposition Products:
Irritating and toxic fumes and gases.
Hazardous Polymerization: Not available.

---

Section 11 - TOXICOLOGICAL INFORMATION
RTECS#:
CAS# 42548-78-7 unlisted.
LD50/LC50:
Not available.
Carcinogenicity:
N-ethylhydroxylamine hydrochloride,97% - Not listed by ACGIH, IARC, NIOSH, NTP, or OSHA.
See actual entry in RTECS for complete information.

---

Section 12 - ECOLOGICAL INFORMATION
For further information, contact Fisher Scientific.

---

Section 13 - DISPOSAL CONSIDERATIONS
Dispose of in a manner consistent with federal, state, and local regulations.

---

Section 14 - TRANSPORT INFORMATION

CDG/CPL
IMO
Not regulated as a hazardous material.
IATA
Not regulated as a hazardous material.
RID/ADR
Not regulated as a hazardous material.
Canadian TDG
No information available.

---

Section 15 - REGULATORY INFORMATION

European/International Regulations
European Labeling in Accordance with EC Directives
Hazard Symbols: Not available.
Risk Phrases:
Safety Phrases:
S 24/25 Avoid contact with skin and eyes.
WGK (Water Danger/Protection)
CAS# 42548-78-7:
Canada
None of the chemicals in this product are listed on the DSL/NDSL list.
WHMIS: Not available.
CAS# 42548-78-7 is not listed on Canada's Ingredient Disclosure List.
Exposure Limits
US FEDERAL
TSCA
CAS# 42548-78-7 is not listed on the TSCA inventory.
It is for research and development use only.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  N-乙基羟胺盐酸盐 在 氯磺酸 作用下， 以 二氯甲烷 为溶剂， 生成 3-Aminoethyl hydrogen sulfate
  参考文献：
  名称：

  α-C-立体化学纯仲磺酰胺的合成

  摘要：

  描述了一种方便的“绿色”立体保留方法，用于在硫原子的 α 位具有不对称中心的富含sp 3的仲磺酰胺。该方法依赖于相应的立体化学纯亚磺酸盐与N-烷基羟胺磺酸（进而容易由N-烷基羟胺和 HSO 3 Cl 制备）的亲电胺化。结果表明，该方法的效率主要受空间因素的影响；它对几个官能团（例如，醚、邻苯二甲酰亚胺或N -Boc 氨基甲酸酯）的耐受性也得到了证实。

  DOI：

  10.1021/acs.joc.2c00480
• 作为产物：
  描述：

  tert-butyl ((tert-butoxycarbonyl)oxy)(ethyl)carbamate 在 盐酸 作用下， 以 1,4-二氧六环 为溶剂， 反应 16.0h， 生成 N-乙基羟胺盐酸盐
  参考文献：
  名称：

  [EN] NITRONE COMPOUNDS AND USE THEREOF
  [FR] COMPOSÉS NITRONES ET LEUR UTILISATION

  摘要：

  本发明涉及新型式（I）的亚硝基化合物，其中A，A1，R1，R2，R3，R4和n如描述中所定义。本发明还涉及它们的制备和用途，用于保护作物免受不受欢迎的植物病原微生物、植物病原真菌和线虫等害虫的侵害。

  公开号：

  WO2020095161A1
• 作为试剂：
  描述：

  2-乙烯基苯甲醛 在 吡啶 、 N-乙基羟胺盐酸盐 作用下， 以 吡啶 、 乙醇 、 叔丁醇 为溶剂， 反应 16.0h， 生成 异喹啉
  参考文献：
  名称：

  New Light-Induced Iminyl Radical Cyclization Reactions of Acyloximes to Isoquinolines

  摘要：

  An efficient photochemical approach for the unusual generation of six-membered heterocyclic rings is reported. Iminyl radicals, generated by the irradiation of acyloximes, participate in intramolecular cyclization processes and in intermolecular addition-intramolecular cyclization sequences.

  DOI：

  10.1021/ol061258i

文献信息

• Dibenzoxepinone Hydroxylamines and Hydroxamic Acids:  Dual Inhibitors of Cyclooxygenase and 5-Lipoxygenase with Potent Topical Antiinflammatory Activity
  作者：R. Richard L. Hamer、John J. Tegeler、Ellen S. Kurtz、Richard C. Allen、Steven C. Bailey、Mary Ellen Elliott、Luther Hellyer、Grover C. Helsley、Penelope Przekop、Brian S. Freed、John White、Lawrence L. Martin

  DOI：10.1021/jm950563z

  日期：1996.1.1

  Hydroxylamine and hydroxamic acid derivatives of a known nonsteroidal antiinflammatory dibenzoxepine series display both cyclooxygenase (CO) and 5-lipoxygenase (5-LO) inhibitory properties. Many of these new dual CO/5-LO inhibitors also exhibit potent topical antiinflammatory activity in the arachidonic acid-induced murine ear edema model. On the basis of their promising profile of in vitro and in

  已知的非甾体类抗炎性二苯并xepine系列的羟胺和羟肟酸衍生物同时显示出环氧合酶（CO）和5-脂氧合酶（5-LO）的抑制特性。这些新的双重CO / 5-LO抑制剂中的许多在花生四烯酸诱导的鼠耳水肿模型中也表现出有效的局部抗炎活性。根据其在体内和体外活性的良好前景，异羟肟酸24h，3-（6,11-dihydro-11-oxodibenz [b，e] oxepin-2-yl）-N-hydroxy-N- +选择+ +甲基丙酰胺（HP 977）和25，3-（6,11-二氢二苯并[b，e]氧杂环丁-2-基）-N-羟基-N-甲基丙酰胺（P10294）作为局部用药的发展候选药物治疗炎症性皮肤病。
• [EN] AMINO PYRAZINE DERIVATIVES AS PHOSPHATIDYLINOSITOL 3-KINASE INHIBITORS<br/>[FR] DÉRIVÉS AMINÉS DE PYRAZINE UTILISABLES EN TANT QU'INHIBITEURS DE LA PHOSPHATIDYLINOSITOL 3-KINASE
  申请人：NOVARTIS AG

  公开号：WO2015162459A1

  公开（公告）日：2015-10-29

  The present invention provides compounds of formula (I) which inhibit the activity of PI 3-kinase gamma isoform, which are useful for the treatment of diseases mediated by the activation of PI 3-kinase gamma isoform.

  本发明提供了一种公式（I）的化合物，该化合物抑制PI 3-激酶γ同工酶的活性，对于治疗由PI 3-激酶γ同工酶激活介导的疾病是有用的。
• [EN] INHIBITORS OF THE HIV INTEGRASE ENZYME<br/>[FR] INHIBITEURS DE L'ENZYME INTEGRASE DU VIH
  申请人：PFIZER

  公开号：WO2006027694A1

  公开（公告）日：2006-03-16

  The present invention relates to compounds of formula (I), or a pharmaceutically acceptable salt or solvate thereof, pharmaceutical compositions comprisingm compounds of formula (I), and their methods of use in treating HIV-infected mammals.

  本发明涉及公式(I)的化合物，或其药物可接受的盐或溶剂化物，包含公式(I)化合物的药物组合物，以及它们在治疗HIV感染哺乳动物中的用途方法。
• [EN] PROCESS FOR THE PREPARATION OF SUBSTITUTED CYCLOSERINES<br/>[FR] PROCÉDÉ DE PRÉPARATION DE CYCLOSÉRINES SUBSTITUÉES
  申请人：SYNGENTA PARTICIPATIONS AG

  公开号：WO2015166094A1

  公开（公告）日：2015-11-05

  The present invention relates to processes for the preparation of substituted cycloserine compounds of formula (I) wherein R1 is C1-C8alkyl, C1-C8haloalkyl, C3-C6cycloalkyl,aryl or aryl substituted by one to five R11, or aryl-C1-C4alkylene or aryl-C1-C4alkylene substituted by one to five R11; and each R11 is independently C1-C4alkyl, C1-C4haloalkyl, C1-C4alkoxy, C1-C4haloalkoxy, cyano or halogen; The invention also relates to intermediates produced by the processes. Compounds of formula (I) are useful intermediates for the production of compounds in the agricultural and pharmaceutical fields.

  本发明涉及制备式(I)的取代环丝氨酸化合物的过程，其中R1为C1-C8烷基，C1-C8卤代烷基，C3-C6环烷基，芳基或被1至5个R11取代的芳基，或芳基-C1-C4烷基或被1至5个R11取代的芳基-C1-C4烷基；每个R11独立地为C1-C4烷基，C1-C4卤代烷基，C1-C4烷氧基，C1-C4卤代烷氧基，氰基或卤素；该发明还涉及由这些过程产生的中间体。式(I)的化合物是在农业和制药领域生产化合物的有用中间体。
• 一类苯并噻吩类化合物及其药物组合物及应用
  申请人：中国科学院上海药物研究所

  公开号：CN111393404B

  公开（公告）日：2023-02-17

  本发明涉及一类苯并噻吩类化合物及其药物组合物及应用。具体地，本发明化合物具有式I所示结构，其中各基团和取代基的定义如说明书中所述。本发明还公开了所述化合物的制备方法及其在抗肿瘤方面的用途。